Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 8, 22 | -0.52
Increased by
+30.67%
|
-0.55
Increased by
+5.45%
|
Aug 9, 22 | -0.64
Increased by
+13.51%
|
-0.57
Decreased by
-12.28%
|
May 10, 22 | -0.68
Decreased by
-4.62%
|
-0.59
Decreased by
-15.25%
|
Mar 17, 22 | -0.65
Increased by
+10.96%
|
-0.74
Increased by
+12.16%
|
Nov 4, 21 | -0.75
Increased by
+25.74%
|
-0.76
Increased by
+1.32%
|
Aug 5, 21 | -0.74
Increased by
+7.50%
|
-0.67
Decreased by
-10.45%
|
May 13, 21 | -0.65
Increased by
+15.58%
|
-0.77
Increased by
+15.58%
|
Mar 18, 21 | -0.73
Decreased by
-1.39%
|
-0.90
Increased by
+18.89%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
0.00
Increased by
+100.00%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-28.05 M
Increased by
+10.62%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
N/A%
|
-29.83 M
Decreased by
-10.91%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 0.00
Decreased by
N/A%
|
-28.23 M
Decreased by
-0.34%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
N/A%
|
-32.61 M
Increased by
+11.33%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 0.00
Decreased by
N/A%
|
-31.39 M
Decreased by
-8.88%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 21 | 0.00
Decreased by
N/A%
|
-26.90 M
Decreased by
-3.57%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 20 | 0.00
Decreased by
N/A%
|
-28.13 M
Decreased by
-24.13%
|
Decreased by
N/A%
Decreased by
N/A%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.